Inhibikase Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q2 2021 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 8.88M shares, a 66.3% increase year-over-year.
  • Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 5.33M shares, a 26.3% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 4.22M shares, a 76.8% decline from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 8.88M +3.54M +66.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 7.54M +2.31M +44.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 6.34M +1.76M +38.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 5.33M +1.11M +26.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 5.34M +1.12M +26.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 5.23M +1M +23.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 4.59M -20.6M -81.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 4.22M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 4.22M -20.9M -83.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 4.22M -8.02M -65.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 25.2M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q3 2021 25.1M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 12.2M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.